Cheap antidepressant shows promise against COVID-19 Fluvoxamine, an inexpensive antidepressant, might help keep patients with COVID-19 from developing severe disease, according to a new study published in The Lancet Global Health on Wednesday. Researchers in Brazil recruited nearly 1,500 COVID-19 patients at high risk for complications
A widely available antidepressant holds promise as a treatment for Covid-19, according to a new study. Covid-19 patients who received fluvoxamine were significantly less likely to require hospitalization than those who didn’t, in the largest clinical trial evaluating the antidepressant’s effect on Covid-19 to date. Fluvoxamine
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
